ICOS Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	1/18/2006 9:43:27 AM
	of 1139

Caprion Pharmaceuticals Announces Biomarker Discovery Collaboration with ICOS Corporation 1/18/2006 8:01:00 AM EST Caprion Pharmaceuticals Inc. today announced an additional research collaboration with ICOS Corporation (Nasdaq:ICOS). The new agreement in biomarker discovery will use Caprion's CellCarta(R) proteomics discovery platform. Caprion will identify pharmacodynamic markers in plasma relating to ICOS' pre-clinical oncology programs. "Caprion looks forward to building on the successful tumor antigen target discovery collaboration initiated with ICOS last year with this second collaboration in the area of biomarkers," noted Dr. Daniel Chelsky, Caprion's Chief Scientific Officer. "We believe that this signals ICOS' confidence in Caprion's ability to discover protein biomarkers that will have a positive impact on their oncology development programs." Caprion's proprietary proteomics platform comprehensively profiles the expression and identity of proteins detected in tissues and blood plasma. Caprion is presently conducting biomarker discovery programs in other indications for several pharmaceutical and biotechnology companies. About Caprion Pharmaceuticals Inc. Caprion is a drug discovery and development company applying its proprietary proteomics technologies to develop innovative pharmaceutical products, initially in oncology and infectious disease. The Company's most advanced program will enter Phase II clinical trials in the US for Shiga-toxin producing E. coli infection (STEC) in the third quarter of 2006. Caprion's proteomics discovery platform - CellCarta(R) - has become a leading means for profiling proteins in blood and solid tumors. Caprion's strategy is to leverage platform discovery and development collaborations in two key areas - oncology and plasma profiling - to fund and further build its own pipeline of clinical programs. In addition to its leading program in STEC, Caprion has signed major research alliances in Colon, Prostate and Lung Cancer with Biogen Idec, AstraZeneca, ICOS Corporation, Abbott Laboratories and ImClone Systems, as well as numerous alliances for plasma profiling and novel biomarker discovery with leading pharmaceutical companies. For more on Caprion, please visit www.caprion.com.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next